Key result
Catheter ablation restores sinus rhythm in tachy-brady syndrome, but ~15% still require subsequent pacemaker implantation.
Why the study?
A significant proportion of patients (7.4%-22.4%) with tachycardia-bradycardia syndrome still require pacemaker implantation after catheter ablation due to intrinsic sinus node dysfunction, and proposed predictive thresholds derived from retrospective or single-center cohorts require prospective validation.
Does catheter ablation reduce the requirement for permanent pacemaker implantation and maintain sinus rhythm compared to primary pacemaker implantation in patients with atrial fibrillation and tachycardia-bradycardia syndrome?
Does catheter ablation reduce the requirement for permanent pacemaker implantation and maintain sinus rhythm compared to primary pacemaker implantation in patients with atrial fibrillation and tachycardia-bradycardia syndrome?
Answers are grounded in this paper and cite their sources.
Although catheter ablation avoids pacemaker implantation in the majority of patients with atrial fibrillation and tachycardia-bradycardia syndrome, 7.4% to 22.4% still require permanent pacing due to intrinsic sinus node dysfunction, underscoring the utility of a phenotype-based risk stratification framework using electrophysiological, imaging, and procedural predictors.
Tachycardia-bradycardia syndrome (TBS), characterized by prolonged sinus pauses following termination of supraventricular tachyarrhythmias (predominantly atrial fibrillation), presents two primary curative strategies: catheter ablation (CA) and pacemaker implantation (PMI). Current guidelines (2024 ESC) recommend CA as a Class IIa intervention to improve symptoms and avoid PMI. Nevertheless, a significant proportion of patients (7.4%-22.4%) still require PMI after CA, primarily due to underlying intrinsic sinus node dysfunction (SND). Several predictors of PMI after CA have been reported, including preprocedural bradycardia-related symptoms, prolonged corrected sinus node recovery time (cSNRT > 550 ms), longer posttachycardia pauses (> 6.3 s), daytime occurrence of the longest sinus pause, autonomic markers such as heart rate variability (HRV), right atrial remodeling reflected by an increased right-to-left atrial volume index ratio (RAVI/LAVI ratio > 0.812), elevated E/Em, atrial or perinodal fibrosis, atrioventricular conduction disease, and procedure-related sinus node artery injury. Most proposed thresholds were derived from retrospective or single-center cohorts and require prospective external validation. This review summarizes current evidence regarding the bidirectional interaction between atrial fibrillation (AF) and SND, distinguishes potentially reversible AF-mediated or vagally mediated SND from intrinsic SND, and proposes a practical treatment-oriented risk stratification framework. This framework classifies patients into three phenotypes: those likely to improve with CA alone, those at high risk of requiring PMI after CA, and those with vagally mediated functional SND who may be candidates for cardioneuroablation (CNA). Emerging strategies, including CNA, conduction system pacing (CSP), leadless pacemakers (LPMs), and biological pacemakers, may further refine individualized management. Future prospective multicenter studies are needed to validate integrated predictive models.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) conducted a review in Atrial fibrillation with tachycardia-bradycardia syndrome. Catheter ablation (and emerging strategies including cardioneuroablation, conduction system pacing, and leadless pacemakers) vs. Pacemaker implantation was evaluated on Requirement for pacemaker implantation after catheter ablation. Catheter ablation restores sinus rhythm in most tachycardia-bradycardia syndrome patients, though 7.4% to 22.4% still require subsequent pacemaker implantation due to intrinsic sinus node dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: